A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: Immunogenicity and anamnestic responses
A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: Immunogenicity and anamnestic responses
复制标题
DOI：
10.1016/j.vaccine.2008.01.021
复制
发表时间：
2008-03-20
期刊：
影响因子：
5.5
通讯作者：
Ohrr, Heechoul
中科院分区：
文献类型：
--
作者：
Sohn, Young Mo;Tandan, J. B.;Ohrr, Heechoul
在参加2000年乙脑疫苗接种运动的98名受试者中，有69人参加了2004年和2005年的试验，以评估单剂SA14-14-2乙脑减毒活疫苗的长期免疫反应。89.9%的研究对象（62/69）在2004年之前保持高水平的中和抗体，其GMT值为133（最小11，最大2991）。2005年接种乙脑疫苗5年后仍有44例乙脑疫苗阳性，其中和抗体阳性率为63.8%（44/69）比14.5%(10/69)，显著高于未接种乙脑疫苗的对照组69例（P < 0.05）。2005年中和抗体血清阴性的24名受试者（第一组）在2006年再次接种了第二次疫苗。此外，2005年纳入的49名血清阴性（第2组）受试者在2006年接种了一剂乙脑初级疫苗。接种7 d后，1组血清阳性率为76.5%(13/17),168.52（最小38，最大2173），2组无血清转化。第30天，1组血清阳性率为82.4% (14/17)，GMT为392.01 (Min 22, Max 2197)， 2组血清阳性率为75.7% (28/37)，GMT为45.72 （Min 12, Max 505）。我们观察到单剂SA14-14-2乙脑减毒活疫苗的中和抗体持续存在，4年后为89.9%，5年后为63.8%，并且在首次接种疫苗后血清阴性的患者中，在加强剂量后第7天出现快速的二次免疫反应。在乙脑流行地区，单剂乙脑活疫苗可以有效地提供长期保护，在这些地区，接种者很可能发生自然增强。然而，对于乙脑非流行地区的人群，一剂乙脑活疫苗是否足够，还需要进一步的研究来支持。(C) 2008 Elsevier Ltd版权所有。
Out of 98 subjects who had participated in the 2000 JE vaccination campaign, 69 people were enrolled in the tests of 2004 and 2005 for the evaluation of long term immune response of a single dose of live attenuated SA14-14-2 JE vaccine. 89.9% of study subjects (62/69) had maintained a high level of neutralizing antibody until 2004 as their GMT was measured as 133 (Min 11, Max 2991). Forty-four subjects were still positive in 2005, 5 years after JE vaccination, and their neutralizing antibody positive rate was significantly higher than that of 69 age-sex matched unvaccinated control subjects: 63.8% (44/69) vs. 14.5% (10/69) (P < 0.05). Twenty-four subjects (Group 1) who were seronegative for neutralizing antibody at the 2005 test were given a second dose for revaccination in 2006. Also 49 seronegative (Group 2) subjects who were enrolled as a control group in 2005 were given one dose of primary JE vaccine in 2006. Seven days after vaccination, seropositive rate was discovered to be 76.5% (13/17) and 168.52 (Min 38, Max 2173) in Group 1, white no seroconversion in Group 2. On the 30th day, seropositive rate and GMT were 82.4% (14/17) and 392.01 (Min 22, Max 2197) in Group 1, white 75.7% (28/37) and 45.72 (Min 12, Max 505) in Group 2, respectively. We observed the persistence of neutralizing antibody of single dose of live attenuated SA14-14-2 JE vaccine, 89.9% after 4 years and 63.8% after 5 years, and a rapid secondary immune response on the seventh day after booster dose among those who had been seronegative in spite of the first dose of vaccine. Single dose of live JE vaccine could be effective to provide a long-term protection in JE endemic area, where natural boosting is quite probable in the vaccinees. However, further studies should be carried out to support whether one dose of live JE vaccine is sufficient for people in JE non-endemic area. (C) 2008 Elsevier Ltd. All rights reserved.